Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2025-11-13 Major Shareholding Noti…
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 100% confidence The document is a declaration of crossing shareholding thresholds (franchissement de seuils) by Heights Capital Management for Gensight Biologics S.A. It details the percentage of capital and voting rights held, the number of shares, and related convertible securities. It references article L. 233-7 of the French commercial code, which governs notifications of significant shareholdings. There is no financial report, earnings data, or management discussion. The document is a notification of a major shareholding change, fitting the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding disclosure, confirming this classification with high confidence.
2025-11-13 French
Inside Information / Other news releases
Capital/Financing Update Classification · 100% confidence The document is a press release from GenSight Biologics announcing a successful fundraising event involving the issuance of new shares and warrants. It details the financial terms, the use of proceeds, and the impact on the company's shareholding structure. This falls under the category of capital and financing updates, as it describes a specific fundraising transaction rather than a general regulatory filing or a periodic report.
2025-11-10 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 100% confidence The document is a press release from GenSight Biologics announcing a capital raise of approximately €2 million through the issuance of new shares and warrants. It details the financial structure, the investors involved, the use of proceeds, and the impact on the company's share capital. This falls under the category of capital and financing updates, as it describes a specific fundraising event and its associated capital structure changes.
2025-11-10 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release from GenSight Biologics announcing regulatory authorization for an 'Individual Patient Expanded Access' program for their drug candidate GS010/LUMEVOQ in the US. It details clinical development status, manufacturing updates, and strategic focus. As it is a general corporate announcement regarding regulatory progress and operational updates that does not fit into specific categories like financial results (ER), dividends (DIV), or board changes (MANG), it is classified as a general regulatory filing/announcement.
2025-10-30 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release from GenSight Biologics announcing regulatory approval for a compassionate use (Expanded Access) treatment of a patient in the US. It provides updates on clinical development, manufacturing partnerships, and regulatory discussions with the ANSM. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. It is a corporate regulatory announcement regarding operational and clinical progress, which falls under the RNS (Regulatory Filings) category.
2025-10-30 French
Informations privilégiées / Communiqué sur comptes, résultats
Capital/Financing Update Classification · 95% confidence The document is a press release from GenSight Biologics detailing its cash position as of September 30, 2025, and subsequent financing activities. It provides specific financial figures regarding cash and cash equivalents and discusses the company's financial outlook and capital structure. While it mentions financial data, it is a short, periodic update on liquidity and financing rather than a full quarterly or annual report. It fits best under 'Capital/Financing Update' (CAP) as it focuses on cash position and recent fundraising, or potentially 'Regulatory Filings' (RNS) as a general corporate announcement. Given the explicit focus on cash position and financing updates, CAP is the most precise classification.
2025-10-07 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.